Prestige Biopharma publishes preclinical data on its first-in-class pancreatic cancer treatment PBP1510 (ulenistamab)

Mar 16, 2022

Prestige BioPharma published preclinical data on its first-in-class pancreatic cancer treatment PBP1510 (ulenistamab).  PBP1510 is being developed as a potential treatment for pancreatic cancer and is currently in Ph 1/2a trials in France and Spain.

Print Page Mail Article